Abstract
Bivalirudin compared with platelet glycoprotein IIbIIIa inhibitors (GPI) was associated with reduced bleeding, increased stent thrombosis and improved survival in patients undergoing primary PCI (PPCI) in the HORIZONS AMI trial. These findings have not been externally corroborated. Our study cohort
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have